PeptideDB

α7 Nicotinic receptor agonist-1 220100-05-0

α7 Nicotinic receptor agonist-1 220100-05-0

CAS No.: 220100-05-0

α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 is useful in
Data collection:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 is useful in psychiatric disorders (such as schizophrenia, manic or manic depression, and anxiety disorders) and intellectual disabilities (such as AD/Alzheimer's disease, learning deficits, cognitive deficits, attention deficit, memory loss, dementia with Lewy bodies, and attention deficit hyperactivity disorder).

Physicochemical Properties


CAS # 220100-05-0
Appearance Light yellow to light brown solid powder
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets α7 nAChR[1].
References

[1]. Novel aralkyl amines of spirofuropyridines useful in therapy. Patent WO2000042044A1.


Solubility Data


Solubility (In Vitro) DMSO: 100 mg/mL (432.36 mM)
Solubility (In Vivo) Solubility in Formulation 1: ≥ 2.08 mg/mL (8.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.08 mg/mL (8.99 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

 (Please use freshly prepared in vivo formulations for optimal results.)